Abstract LB-73: Nuclear S100A4 is a novel prognostic marker in colorectal cancer

Abstract

Abstract Background and Aims: Current staging classifications in colorectal cancer are not able to accurately predict patient outcome, and the need for novel prognostic markers is evident. S100A4 is a Ca2+-binding protein which promotes metastasis in several tumor types, and the aim of the present study was to investigate the prognostic impact of S100A4 expression in colorectal cancer. Methods: 242 patients with curatively resected adenocarcinoma of the colon or rectum were prospectively included in the study at the time of surgery. S100A4 expression was analyzed by immunohistochemistry, and associations with clinicopathological variables and patient outcome were investigated. Results: Nuclear expression of S100A4 was observed in 29% and cytoplasmic expression was observed in 64% of the tumors. In univariate analysis, nuclear S100A4 was a significant predictor of metastasis-free (P= .006) and overall survival (P= .01), whereas cytoplasmic S100A4 was not associated with patient outcome. In multivariate analysis, nuclear localization was associated with metastasis-free (P= .03) and overall survival (P= .02). Interestingly, the prognostic impact was largely confined to TNM stage II, and stage II patients with tumors expressing nuclear S100A4 had a similar prognosis as stage III patients. Conclusions: Nuclear expression of S100A4 is a novel prognostic marker in colorectal cancer, and the prognostic value in TNM stage II suggests that nuclear S100A4 could be used in the stratification of stage II patients for adjuvant treatment. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-73.